SGLT2 / SGLT1 inhibitor combinations are used to lower the risk of cardiovascular events in people with heart failure. They can also help reduce these risks in people who have Type 2 diabetes, chronic kidney disease, and at least one other cardiovascular risk factor. These medications work by blocking proteins called sodium-glucose co-transporters (SGLT2 and SGLT1), which help your kidneys remove excess glucose (sugar) and sodium (salt) from your blood through your urine. This can helps reduce the strain on your heart, blood vessels, and kidneys. These medications are available as oral tablets. An example of this combination is sotagliflozin (Inpefa).
